|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:temple
|
|
gptkbp:activities
|
EGFR inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2015
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Tagrisso
|
|
gptkbp:clinical_trial
|
Phase III
second-line treatment
first-line treatment
FLAURA
AUR A1
AUR A2
AUR A3
|
|
gptkbp:contraindication
|
hypersensitivity to osimertinib
|
|
gptkbp:developed_by
|
gptkb:temple
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tagrisso
|
|
gptkbp:indication
|
metastatic non-small cell lung cancer
|
|
gptkbp:ingredients
|
gptkb:osimertinib
C18 H21 N7 O3 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
2026
|
|
gptkbp:is_atype_of
|
L01 X E30
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
48 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Tagrisso
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:pharmacokinetics
|
oral bioavailability 60%
|
|
gptkbp:population
|
adults
|
|
gptkbp:previous_name
|
gptkb:osimertinib
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_information_on
|
ESMO guidelines
NCCN guidelines
|
|
gptkbp:research_focus
|
gptkb:EGFR_T790_M_mutation
brain metastases
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:scholarships
|
gptkb:stock_market_index
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
|
|
gptkbp:targets
|
EGFR mutations
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:weight
|
393.47 g/mol
|